Work

Survival Benefit of Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study

Year: 2026
Type: article
Study design: Observational Study
Abstract: Introduction: Atezolizumab plus bevacizumab (Atezo/Bev) improves overall survival (OS) and progression-free survival (PFS) in hepatocellular carcinoma (HCC). Whether adding on-demand transcatheter arterial chemoembolization (TACE) to Atezo/Bev (ABC-TACE) adds benefit, and whether this depends on the tumor response already achieved, remains unclear. Methods: We retrospectively analyzed 567 patients with unresectable HCC given Atezo/Bev at 16 Japanese institutions. Those who underwent on-demand TACE during Atezo/Bev treatment formed the ABC-TACE group (n = 90) and those who did not the Atezo/Bev-alone control group (n = 477). Because TACE was performed at a variable time (median 199 days after initiation), the primary analysis entered TACE as a time-dependent covariate, with landmark analyses at 3, 6, and 9 months. An exploratory analysis stratified the cohort by the response documented before TACE: partial response (PR), stable disease (SD) with or without shrinkage, and progressive disease (PD). Adverse events were graded by CTCAE v5.0, and the albumin-bilirubin (ALBI) score was compared by mixed-effects modeling. Results: Adjusted for ten prespecified covariates, TACE was associated with longer OS (hazard ratio [HR] = 0.48, 95% confidence interval [CI]: 0.32–0.71; p < 0.001) and PFS (HR = 0.62, 95% CI: 0.42–0.92; p = 0.018). Assigning exposure at any time, which ignores immortal time, gave HRs of 0.37 and 0.34. Landmark analyses were concordant in direction. Grade ≥3 adverse events (27.8% versus 35.2%; p = 0.184) and ALBI trajectories (ever- vs never-TACE; p = 0.198) did not differ significantly. Stratified by pre-TACE response (exploratory), OS HRs were 0.12 for PR, 0.42 and 0.53 for the two SD strata, and 1.51 for PD (interaction p = 0.020). The estimates are imprecise (only 2 deaths in the PR stratum followed embolization), the interaction did not persist when the PD stratum was excluded (p = 0.097), and PFS showed no corresponding interaction (p = 0.589). Conclusion: In this real-world cohort, ABC-TACE was associated with longer survival than Atezo/Bev alone. The response-stratified analyses are exploratory and do not establish effect modification. These findings are hypothesis-generating rather than practice-changing, and prospective response-stratified evaluation is required before a response-guided approach can be adopted.
Source: Liver Cancer
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,590
OpenAlex ID: W7235708444
FWCI:
Cites:
Cited by:
Related to: 10